DelveInsight’s “Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast – 2034” provides a comprehensive analysis of Non-Cystic Fibrosis Bronchiectasis (NCFB), including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report evaluates current treatment practices, emerging therapeutic options, market share of individual therapies, and the market size for NCFB from 2020 to 2034, segmented across the seven major markets (7MM). Additionally, it outlines treatment algorithms, key market drivers and barriers, unmet medical needs, and future opportunities, thereby offering a detailed assessment of the evolving NCFB therapeutic landscape.
Discover Key Insights into the Non-Cystic Fibrosis Bronchiectasis Market with DelveInsight’s In-Depth Report @ Non-Cystic Fibrosis Bronchiectasis Market Size
Key Takeaways from the Non-Cystic Fibrosis Bronchiectasis Market Report
- According to DelveInsight’s epidemiology model, in the 7MM, the total diagnosed prevalent cases of NCFB were approximately 1,028,651 in 2023. This number is anticipated to rise during the forecast period (2024-2034), driven by increased awareness and screening, along with advancements in diagnostic techniques.
- In 2023, the US accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 380,711 cases, while France accounted for the least, with only 37,576 cases.
- Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases of NCFB, with approximately 224,976 cases in 2023, followed by Spain with approximately 149,236 cases, and Italy with nearly 89,584 cases.
- Among the severity-specific diagnosed prevalent cases of NCFB in EU4 and the UK in 2023, there were approximately 235,481 moderate cases, around 163,649 severe cases, and 152,230 mild cases.
- Among the gender-specific cases of NCFB in the UK in 2023, there were approximately 130,486 cases for females and around 94,490 cases for males.
- In Japan in 2023, the majority of etiology-specific diagnosed prevalent cases of NCFB were attributed to unknown or idiopathic causes, accounting for 32,837 cases.
- In 2023, Japan had approximately 96,580 diagnosed prevalent cases of NCFB.
- The leading Non-Cystic Fibrosis Bronchiectasis Companies such as Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others.
- Promising Non-Cystic Fibrosis Bronchiectasis Therapies such as Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others.
Stay ahead in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market with DelveInsight’s Strategic Report @ Non-Cystic Fibrosis Bronchiectasis Market Outlook
Non-Cystic Fibrosis Bronchiectasis Overview
Non-cystic fibrosis bronchiectasis (NCFBE) is a chronic respiratory disorder characterized by permanent dilation and structural damage of the bronchi, leading to impaired mucus clearance, recurrent infections, and persistent inflammation. Unlike cystic fibrosis–related bronchiectasis, NCFBE arises from diverse causes, including prior infections, immunodeficiencies, autoimmune diseases, and airway obstruction, though many cases remain idiopathic. Patients commonly experience chronic cough, excessive sputum production, dyspnea, and frequent exacerbations that progressively worsen lung function. Diagnosis relies on high-resolution CT imaging, sputum cultures, and clinical assessment. Management focuses on airway clearance, inhaled therapies, antibiotics, and exacerbation prevention. Despite treatment advances, significant unmet needs remain for targeted, disease-modifying therapies.
Non-Cystic Fibrosis Bronchiectasis Epidemiology Segmentation in the 7MM
- Non Cystic Fibrosis Bronchiectasis diagnosed prevalent cases
- Non Cystic Fibrosis Bronchiectasis severity-specific diagnosed prevalent cases
- Non Cystic Fibrosis Bronchiectasis gender-specific diagnosed prevalent cases
- Non Cystic Fibrosis Bronchiectasis etiology-specific diagnosed prevalent cases
- Microbiology of Non Cystic Fibrosis Bronchiectasis patients
Download the report to understand which factors are driving Non-Cystic Fibrosis Bronchiectasis Epidemiology trends @ Non-Cystic Fibrosis Bronchiectasis Prevalence
Marketed Non Cystic Fibrosis Bronchiectasis Drugs
- BRINSUPRI (brensocatib): Insmed
Brensocatib, an oral small-molecule inhibitor targeting dipeptidyl peptidase 1 (DPP1), is being developed by Insmed for the treatment of bronchiectasis, CRSsNP, and other neutrophil-driven conditions. By inhibiting DPP1, brensocatib aims to reduce inflammation by blocking the activation of neutrophil serine proteases (NSPs), such as neutrophil elastase, during neutrophil formation in the bone marrow. Insmed reported positive topline results from the Phase III ASPEN study of brensocatib in patients with NCFB, leading to plans for a New Drug Application (NDA) submission to the US FDA in late 2024.
Emerging Non Cystic Fibrosis Bronchiectasis Drugs
- Inhaled Colistimethate Sodium (CMS I-neb): Zambon
CMS I-neb is an investigational inhaled therapy for adults with NCFB colonized by P. aeruginosa, potentially offering a first-in-class treatment option. It uses colistimethate sodium, a prodrug of colistin, a polymyxin antibiotic targeting aerobic Gram-negative pathogens, including drug-resistant P. aeruginosa. By disrupting the bacterial cell membrane, colistin causes cell death and serves as a last-resort treatment for infections like carbapenem-resistant P. aeruginosa.
- FASENRA (benralizumab): AstraZeneca
FASENRA (benralizumab) is a monoclonal antibody that targets the IL-5 receptor alpha on eosinophils, facilitating the recruitment of natural killer cells to induce apoptosis, resulting in rapid and near-complete depletion of blood and tissue eosinophils in most patients. FASENRA is currently under investigation for treating adult patients with Non-Cystic Fibrosis Bronchiectasis associated with eosinophilic inflammation (NCFB + EI). According to clinicaltrials.gov, FASENRA completed Phase III clinical trials for this indication in April 2024.
Non Cystic Fibrosis Bronchiectasis Drugs Analysis
The Non Cystic Fibrosis Bronchiectasis treatment involves several drug classes tailored to manage symptoms, reduce exacerbations, and control underlying inflammation. Antibiotics, both oral and inhaled, are essential for managing chronic bacterial colonization, particularly against pathogens like P. aeruginosa. Macrolides, often used for their anti-inflammatory properties, are beneficial in reducing exacerbation frequency. Bronchodilators, including beta-agonists and anticholinergics, help alleviate airway obstruction, while corticosteroids are used to address inflammation, although their role remains limited due to potential side effects. Mucolytic agents improve mucus clearance, and emerging anti-inflammatory agents targeting neutrophilic inflammation, such as DPP1 inhibitors, represent innovative approaches. Together, these drug classes form a comprehensive yet evolving treatment landscape for NCFB, addressing its multifaceted pathophysiology. The Non-Cystic Fibrosis Bronchiectasis drugs market is growing, driven by rising prevalence and demand for effective antibiotic and anti-inflammatory treatments.
Get In-Depth Knowledge on Non-Cystic Fibrosis Bronchiectasis Market Trends and Forecasts with DelveInsight @ Non-Cystic Fibrosis Bronchiectasis Treatment Market
Non-Cystic Fibrosis Bronchiectasis Companies and Drugs
- Brensocatib: Insmed/AstraZeneca
- Inhaled Colistimethate Sodium (CMS I-neb): Zambon
- FASENRA (benralizumab): AstraZeneca
- ARINA-1 (RVN-301): Renovion
- HSK31858: Haisco Pharmaceutical Group/Chiesi Farmaceutici S.p.A
- AP-PA02: Armata Pharmaceuticals
- Ensifentrine (Nebulizer): Verona Pharma
- Itepekimab: Sanofi/Regeneron Pharmaceuticals
- BI 1291583: Boehringer Ingelheim
- CHF 6333: Chiesi Farmaceutici S.p.A.
- CSL787: CSL
Non-Cystic Fibrosis Bronchiectasis Market Outlook
The market for NCFB is poised for significant growth due to the evolving landscape of pharmacological and non-pharmacological interventions addressing the complex pathophysiology of the disease. Current therapeutic strategies encompass a range of drug classes, including antibiotics, corticosteroids, bronchodilators, and mucolytics, with inhaled antibiotics demonstrating efficacy in managing chronic bacterial infections and reducing exacerbation rates. Emerging therapies, such as Brensocatib, a Dipeptidyl Peptidase 1 (DPP1) inhibitor, and BI 1291583, a cathepsin C inhibitor, target neutrophilic inflammation through distinct mechanisms, thereby offering novel approaches to improve patient outcomes.
Scope of the Non-Cystic Fibrosis Bronchiectasis Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Non-Cystic Fibrosis Bronchiectasis Companies- Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others.
- Non-Cystic Fibrosis Bronchiectasis Therapies- Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others.
- Non-cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-cystic Fibrosis Bronchiectasis Current marketed and Non-cystic Fibrosis Bronchiectasis Emerging Therapies
- Non-cystic Fibrosis Bronchiectasis Market Dynamics: Non-cystic Fibrosis Bronchiectasis Market Drivers and Non-cystic Fibrosis Bronchiectasis Market Barriers
- Non-cystic Fibrosis Bronchiectasis Unmet Needs, KOL’s views, Analyst’s views, Non-cystic Fibrosis Bronchiectasis Market Access and Reimbursement
Download sample report @ Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Drugs Market
Table of Contents
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Epidemiology and Market Forecast Methodology
5. Executive Summary
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Non-Cystic Fibrosis Bronchiectasis: Market Analysis
13. Key Opinion Leaders’ Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
